Covicept Therapeutics initiates a Phase 2 clinical study with PJS-539, an oral small molecule for the treatment of patients with COVID-19 (SARS-CoV-2) Covicept has initiated a Phase 2 multi-center
Covicept Therapeutics initiates a Phase 2 clinical study with PJS-539, an oral small molecule for the treatment of patients with COVID-19 (SARS-CoV-2) | Comunicados | Edición USA efe.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from efe.com Daily Mail and Mail on Sunday newspapers.
(Image credit: PM Images via Getty Images)
Every 40 seconds, someone in the U.S. has a heart attack, which amounts to about
805,000 heart attacks every year. Of course, this statistic applies only to humans. But what about other animals do they also experience this debilitating and potentially deadly condition?
For the most part, other animals don t get heart attacks not even one of our closest living relatives,
Pan troglodytes). Nonhuman animals experience other cardiac problems, but as far as scientists know, heart attacks are rare in other creatures. In general, animals don t naturally die from the typical heart attack that you see where you clog up the coronary arteries in humans, Philip Gordts, an assistant professor who studies
Posted on 7468
Forbion, a leading European life sciences venture capital firm, today announces a $2.3m seed investment in newly formed CoviCept Therapeutics, Inc. (“CoviCept”), a California-based company that is developing a small molecule that inhibits the replication of SARS-CoV-2 (COVID-19) and other RNA viruses.
CoviCept’s lead molecule has a unique mechanism of action that is based on interference of a host cell protein and is therefore expected to have a low risk of viral resistance. It has been demonstrated to inhibit SARS-CoV-2 replication in a relevant mammalian model at a clinically relevant dose. A manufacturing process for the lead compound has been established and it has demonstrated good bioavailability and safety in humans in phase 1 studies.